Trial Profile
Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID ΔM2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Feb 2018
Price :
$35
*
At a glance
- Drugs Respiratory syncytial virus vaccine live (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; Pharmacodynamics
- 12 Feb 2018 Status changed from active, no longer recruiting to completed.
- 17 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Nov 2016 New trial record